systemic lupus erythematosus
Rheumatology · 2019–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| anifrolumab Treatment of adult patients with severe systemic lupus erythematosus (SLE) with high disease activity (SLEDAI-2K ≥10) despite standard of care (SOC) triple… | Mar 2024 | Recommended with restriction | 142 individuals Australasian Society of Clinical Immunology and Allergy · Australian Rheumatology Association · CreakyJoints Australia · Global Healthy Living Foundation Australia |
| anifrolumab Treatment of adult patients with severe systemic lupus erythematosus (SLE) with high disease activity (SLEDAI-2K ≥10) despite standard of care. | Mar 2023 | Not recommended | 11 individuals Australasian Society of Clinical Immunology and Allergy · Australian Rheumatology Association · National Aboriginal Community Controlled Health Organisation |
| anifrolumab Treatment of adult patients with systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard of care, added to standard therapy… | Jul 2022 | Not recommended | input received Musculoskeletal Australia · Lupus Australia · National Aboriginal Community Controlled Health Organisation · Australian Rheumatology Association |
| belimumab Active auto-antibody positive systemic lupus erythematosus (SLE) with a high degree of disease activity, despite defined ongoing standard of care. | Jul 2020 | Not recommended | 7 individuals National Aboriginal Community Controlled Health Organisation · Pain Australia |
| belimumab Active auto-antibody positive systemic lupus erythematosus (SLE) with a high degree of disease activity, despite defined ongoing standard of care. | Nov 2019 | Not recommended | 9 individuals |
Who spoke
National Aboriginal Community Controlled Health Organisation · Australian Rheumatology Association · Australasian Society of Clinical Immunology and Allergy · Musculoskeletal Australia · Lupus Australia · CreakyJoints Australia · Global Healthy Living Foundation Australia · Pain Australia
What the PBS pays
$1M in government benefit over 2024–25, across 877 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| anifrolumab | $1.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| hydroxychloroquineAPO-HYDROXYCHLOROQUINE hydroxychloroquine sulfate 200 mg tablet bottle | 1994 | 6 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.